GTX peptides consist of several potential drug candidates under preclinical development that, unlike RMC-035, are designed to mimic a smaller portion (shorter fragments) of the endogenous (human) A1M protein. Other key differences between RMC-035 and GTX peptides are that the latter can be self-administered through subcutaneous injection and allow for chronic long-term treatment.
GTX peptides have shown robust therapeutic effects in various models of kidney disease. The company has identified several development opportunities for GTX peptides, including for advanced kidney disease with the aim of eliminating the need for dialysis and kidney transplantation, as well as for several rare kidney diseases associated with a high risk of end-stage renal disease (ESRD), such as Alport syndrome.
GTX peptides are smaller in size than RMC-035 and are chemically produced without the use of bacteria or living cells.
Intellectual property rights for the GTX platform have been secured through multiple patent applications, with expected protection until 2044.